Christos Liaskos, Eleni Patrikiou, Theodora Simopoulou, Lazaros I. Sakkas & Dimitrios P. Bogdanos
Please wait while flipbook is loading. For more related info, FAQs and issues please refer to DearFlip WordPress Flipbook Plugin Help documentation.
This commentary underlines the need for continuous research on interstitial lung disease related to autoimmune rheumatic diseases. Amongst the numerous unmet needs, there is the urgent demand for better stratification of patients in terms of prognosis or response to treatment. Disease-related or disease-specific autoantibodies have been proven useful diagnostic tools but their clinical significance in stratifying patients who are gone have a poor prognosis is still a matter of debate. Autoantibody testing relates to the underlying cause of the disease, which in our case can vary amongst a plethora of autoimmune rheumatic diseases, such as systemic sclerosis, rheumatoid arthritis, mixed connective tissue disease or anti-synthetase syndrome. Better stratification of the patients using prompt biomarkers may assist efforts for very early intervention and better outcome.
